BIOC On Other Exchanges
text size: T | T
Back to Snapshot
Company Description

Contact Info

5810 Nancy Ridge Drive

San Diego, CA 92121

United States

Phone: 858-320-8200

Fax: 858-320-8225

iocept, Inc., a cancer diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC), and circulating tumor DNA (ctDNA) tests utilizing a standard blood sample, or ‘liquid biopsy’. The company’s tests provide information to oncologists and other physicians that enable them to select the most appropriate treatment for their patients based on better, timelier and more-detailed data on the characteristics of tumors. The company’s OncoCEE-BR for breast cancer test, OncoCEE-LU for NSCLC test and OncoCEE-GA for gastric cancer test and its planned tests utilize its Cell Enrichment and Extraction, or CEE, technology for the enumeration and analysis of CTCs, and its CEE-Selector technology for the detection and analysis of ctDNA, each performed on a standard blood sample. The CEE technology is an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing real-time biomarker monitoring with a standard blood sample. The CEE-Selector technology enables mutation detection with enhanced sensitivity and specificity and is applicable to nucleic acid from CTCs or other sample types, such as blood plasma for ctDNA. Business Strategy The company plans to provide oncologists and other physicians with a straightforward means to profile and characterize their patients’ tumors on a real-time basis by analyzing CTCs and ctDNA found in standard blood draws. Research and Development The company incurred research and development expenses of $4.5 million, as of December 31, 2014. Intellectual Property Patents: As of December 31, 2014, the company owned eight issued U.S. patents, five pending U.S. patent applications and corresponding patents and patent applications internationally. In addition, as of December 31, 2014, the company co-owned two pending U.S. patent applications, as well as corresponding foreign patents and applications. Competition The company’s competitors include Janssen Diagnostics, LLC, Atossa Genetics, Alere (Adnagen), Illumina, Apocell, EPIC Sciences, Clearbridge Biomedics, Cynvenio Biosystems, Fluxion Biosciences, Guardant Health, RareCells, and Silicon Biosystems. Significant Events In June 2015, Biocept entered into a clinical collaboration with Sarah Cannon Research Institute. The company said that the collaboration aims to determine the clinical utility of detecting biomarkers present in circulating tumor cell (CTC) and circulating tumor DNA (ctDNA) in blood samples for estrogen positive (ER+) breast cancer patients using Biocept's OncoCEE technology. In December 2015, Biocept, Inc. announced a collaboration with Baylor College of Medicine to develop minimally invasive blood-based tests using Biocept's circulating tumor cell (CTC) and circulating tumor DNA (ctDNA) molecular diagnostic assay platforms to detect mutations in the estrogen receptor gene (ESR1). History Biocept, Inc. was founded in 1997 in California.


The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. does not create or control the content.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

BIOC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BIOC.
View Industry Companies

Industry Analysis


Industry Average

Valuation BIOC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 17.9x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.2x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact BIOCEPT INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at